TRV GP V, LLC

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 10, 2026), TRV GP V, LLC reported 3 stock positions worth $498.2 million. Its top holding was Rapport Therapeutics (RAPP) at 52.5% of the portfolio, followed by Septerna (SEPN, 41.8%) and Maze Therapeutics (MAZE, 5.7%). Compared with Q1 2026, it reduced 1. The biggest sale was Rapport Therapeutics (RAPP, shares −12%).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001990717
Portfolio Value
$498.2M (Q2 2026)
SEC Filing
0001193125-26-340725 ↗ filed Aug 10, 2026

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q4 2024: $294.0M Q4 2024 Q1 2025: $125.1M Q1 2025 Q2 2025: $165.7M Q2 2025 Q3 2025: $353.5M Q3 2025 Q4 2025: $429.2M Q4 2025 Q1 2026: $401.0M Q1 2026 Q2 2026: $498.2M $498.2M Q2 2026

Holdings 3 stocks · $498.2M
RAPP Rapport Therapeutics Inc. 52.53% 6,280,525 $261.7M Reduce -12.0%
SEPN Septerna Inc. 41.78% 6,215,591 $208.2M No change
MAZE Maze Therapeutics Inc. 5.69% 950,800 $28.4M No change

Portfolio Sells Q1 2026 → Q2 2026
RAPP Rapport Therapeutics Inc. Reduce -12.0% 52.53% −3.15

Portfolio Buys Q1 2026 → Q2 2026
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$498.2MRAPP, SEPN, MAZE
Q1 2026 3$401.0MRAPP, SEPN, MAZE
Q4 2025 3$429.2MRAPP, SEPN, MAZE
Q3 2025 3$353.5MRAPP, SEPN, MAZE
Q2 2025 4$165.7MRAPP, SEPN, MAZE, CRGX
Q1 2025 4$125.1MRAPP, SEPN, MAZE, CRGX
Q4 2024 3$294.0MSEPN, RAPP, CRGX